UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 19, 2016
CytoDyn Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-49908 |
|
75-3056237 |
(State or other jurisdiction
of incorporation) |
|
(SEC
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
1111 Main Street, Suite 660
Vancouver, Washington |
|
98660 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (360) 980-8524
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 |
Entry into a Material Definitive Agreement. |
On January 19, 2016, CytoDyn Inc., a Delaware
corporation (the Company) entered into an amendment (the Amendment) to its existing Consulting Agreement with Denis R. Burger, Ph.D., dated February 21, 2014, as previously amended November 3, 2014 (the
Consulting Agreement).
The Amendment names Dr. Burger, who is currently a member of the Board of Directors, to the non-executive
position of Chief Science Officer and increases Dr. Burgers advisory responsibilities in that capacity. The Amendment also increases the compensation payable to Dr. Burger under the Consulting Agreement to $20,000 in cash per month,
which is in addition to any fees that Dr. Burger currently earns as a director. The Amendment was approved by the Audit Committee of the Board of Directors.
A copy of the Amendment is filed as Exhibit 10.1 to this Form 8-K and is incorporated into this Item 1.01 by reference.
Item 3.02 |
Unregistered Sales of Equity Securities. |
Between December 29, 2015 and January 22, 2016, the
Company issued in private placements to accredited investors an aggregate of 4,832,321 shares of its common stock, par value $0.001 per share (the Common Stock), together with warrants to purchase an aggregate of 2,416,151 shares of
Common Stock at an exercise price of $0.75 per share, for aggregate gross proceeds to the Company of approximately $3.6 million. The Company also became obligated to issue warrants to purchase an aggregate of 519,002 shares of Common Stock, along
with a cash payment of approximately $0.4 million, as a fee to the placement agent in certain of the transactions. All of the foregoing warrants have a five-year term, running from their respective dates of issuance, and are immediately exercisable.
The Company relied on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act) in connection with the foregoing transactions.
In addition, on December 21, 2015 and January 4, 2016, the Company issued to certain third-party consultants warrants to purchase an aggregate of 290,000
shares of Common Stock, as consideration for services provided to the Company. One warrant covering 50,000 shares has an exercise price of $0.81 per share and a 10-year term, vesting in two equal semi-annual installments beginning on May 21,
2016. The other warrant covering 240,000 shares has an exercise price of $0.92 per share and a 10-year term, vesting in four equal quarterly installments commencing on January 4, 2016. The Company relied on the exemption provided by Section 4(a)(2)
of the Securities Act in connection with the foregoing transactions.
After giving effect to all of the foregoing transactions, the number of shares of
Common Stock outstanding as of January 22, 2016 was 102,938,421.
On January 20, 2016, the Company issued a press release announcing the Amendment to
the Consulting Agreement with Dr. Burger. A copy of the press release is filed as Exhibit 99.1 to this Form 8-K.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits. The following exhibits are filed herewith:
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
10.1 |
|
Amendment No. 2 to Consulting Agreement, dated January 19, 2016, between CytoDyn Inc. and Denis R. Burger, Ph.D. |
|
|
99.1 |
|
Press Release dated January 20, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CytoDyn Inc. |
|
|
|
|
January 22, 2016 |
|
|
|
By: |
|
/s/ Michael D. Mulholland |
|
|
|
|
Name: |
|
Michael D. Mulholland |
|
|
|
|
Title: |
|
Chief Financial Officer |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
10.1 |
|
Amendment No. 2 to Consulting Agreement, dated January 19, 2016, between CytoDyn Inc. and Denis R. Burger, Ph.D. |
|
|
99.1 |
|
Press Release dated January 20, 2016. |
Exhibit 10.1
CYTODYN INC.
AMENDMENT
NO. 2 TO CONSULTING AGREEMENT
This Amendment No. 2 to Consulting Agreement (this Agreement) is made and entered into
on January 19, 2016 and effective as of January 19, 2016 (the Effective Date), by and between CytoDyn Inc., a Delaware corporation (the Company), and Denis R. Burger, Ph.D., an individual (Consultant).
WHEREAS, Consultant has served as an outside director of the Companys Board of Directors (the Board) since
February 7, 2014; and
WHEREAS, Consultant has over 25 years of experience managing scientific, operational, financial, and executive
responsibilities in the biotech industry; and
WHEREAS, Company and Consultant entered into a Consulting Agreement on February 14,
2014 (the Agreement), pursuant to which the Company retained Consultant to advise the Companys executive management team (the Team) and perform such other services as set forth in the Agreement);
WHEREAS, Company and Consultant entered into an amendment to the Agreement effective November 3, 2014 (Amendment No. 1);
WHEREAS, Company and Consultant wish to amend again certain terms of the Agreement, as amended:
NOW, THEREFORE, in consideration of the material promises set forth herein and for other good and valuable consideration, the parties agree as
follows:
1. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Original Agreement.
2. Amendment to Section 2. Section 2 of the Agreement is hereby further amended by adding a new Section 2(f) as follows:
2(f) Consultant shall be appointed the Companys Chief Science Officer and shall provide the Company with strategic
advice with respect to scientific matters and leadership to explore and evaluate expanded opportunities for PRO 140.
3. Amendment to
Section 4(a). Section 4(a) of the Agreement is hereby amended by deleting the existing paragraph 4(a) in its entirety and substituting the following in lieu thereof:
4(a) Monthly Fee. Consultant will receive as compensation hereunder monthly payments of $20,000, in cash, payable on or before the 15th
day of each month, beginning on the Effective Date and for the term of this Agreement.
4. No Other Amendments. Except as expressly
amended herein, the Agreement, as amended shall continue in full force and effect.
1
5. Governing Law. This Amendment shall be governed by, and construed in accordance with,
the laws of the state of Washington without giving effect to the choice of law provisions thereof.
6. Counterparts. For the
convenience of the parties hereto, this Amendment may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement.
7. Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and each of their
successors and assigns, including, without limitation, any successors or surviving entities thereto by operation of merger.
8. Entire
Agreement. The Agreement, as amended hereby, constitutes the entire agreement of all parties hereto with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties hereto
with respect to the subject matter hereof. All references in the Agreement to this Agreement, hereof, hereby and words of similar import shall refer to the Agreement as amended hereby.
IN WITNESS WHEREOF, the parties have set their hands as of the Effective Date.
|
|
|
|
|
|
|
|
|
THE COMPANY CytoDyn
Inc. |
|
|
|
|
|
CONSULTANT Denis R. Burger,
Ph.D. |
|
|
|
|
|
By: |
|
/s/ Nader Z. Pourhassan |
|
|
|
|
|
/s/ Denis R. Burger, Ph.D. |
|
|
Nader Z. Pourhassan President and Chief
Executive Officer |
|
|
|
|
|
Denis R. Burger, Ph.D. |
2
Exhibit 99.1
CYTODYN APPOINTS DENIS R. BURGER, PH.D., AS CHIEF SCIENCE OFFICER
Dr. Burger, former Chairman and CEO of several successful biotechnology companies, named to expanded leadership role
Vancouver, Washington January 20, 2016 CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new
therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Companys Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this
capacity, through an expansion of Dr. Burgers existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune
diseases and cancer. He recently initiated the Companys evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Companys Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell
transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
Dr. Burger was appointed a Director of CytoDyn in February 2014 and named Vice Chairman of the Board of Directors of CytoDyn in August 2014. He is a
life sciences executive with over 30 years of extensive scientific, operational and financial experience in the biotech industry. As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate financing
transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. Dr. Burger is currently lead director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed
company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief
Executive Officer of AVI Biopharma Inc. (now Sarepta Therapeutics), a NASDAQ-listed RNA therapeutics company. He was also a co-founder of Epitope Inc. (now Orasure Technologies, NASDAQ listed), serving as its Chairman from 1981 to 1990.
Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in
Bacteriology and Immunology from the University of California in Berkeley and his Master of Science and Ph.D. degrees in Microbiology and Immunology from the University of Arizona.
Dr. Nader Pourhassan, President and CEO, commented: We are delighted that Dr. Burger has decided to accept this expanded leadership role with
CytoDyn. With our excellent clinical development team at Amarex and a team of leading scientific and medical advisors, we now have a solidified team with Dr. Burger accepting this key role for CytoDyn.
I am honored to be selected for this crucial role in the expansion of PRO 140 into immunologic indications, said Dr. Burger. The target
for PRO 140, CCR5, plays an important role in a vast array of immune mechanisms and CytoDyn is positioned to expand the potential market for PRO 140 by pursuing these non-HIV clinical indications including transplantation, chronic inflammation,
autoimmunity and cancer.
About CytoDyn
CytoDyn
is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading
monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T-cells which prevents
viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from six Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly
reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. CytoDyn intends to continue to
develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. For more information on the Company, please visit www.cytodyn.com.
About PRO 140
PRO 140 belongs to a new class of HIV/AIDS
therapeutics viral-entry inhibitors that are intended to protect healthy cells from viral infection. PRO 140 is a fully humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO
140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist
activity towards CCR5 but does have antagonist activity to CCL5 which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV
viral load in human test subjects. PRO 140 has been designated a fast track product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing
requirements as compared to daily drug therapies currently in use.
Forward-Looking Statements
This press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws, including
statements regarding the Companys Phase 3 and other current and proposed studies and their results and completion. These statements and information represent CytoDyns intentions, plans, expectations, and beliefs and are subject to risks,
uncertainties and other factors, many beyond CytoDyns control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words believe, estimate,
expect, intend, attempt, anticipate, foresee, plan, and similar expressions and variations thereof identify certain of such forward-looking statements or forward-looking
information, which speak only as of the date on which they are made.
CytoDyn disclaims any intention or obligation to publicly update or revise any
forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking
statements or forward-looking information. While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of and expense associated with
research, development, regulatory approval, and commercialization of CytoDyns products and product candidates, including
the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will
not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on CytoDyns products and product candidates will be unfavorable; funding for additional clinical trials may not be available; CytoDyns products may not
receive marketing approval from regulators or, if approved, may fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial
potential of CytoDyns products; CytoDyn, its collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to
product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.
CytoDyn is also subject to additional risks and uncertainties, including risks associated with the actions of its corporate, academic, and other collaborators
and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property litigation; environmental and other risks; and risks that current and pending patent protection for its products may be
invalid, unenforceable, or challenged or fail to provide adequate market exclusivity. There are also substantial risks arising out of CytoDyns need to raise additional capital to develop its products and satisfy its financial obligations; the
highly regulated nature of its business, including government cost-containment initiatives and restrictions on third-party payments for its products; the highly competitive nature of its industry; and other factors set forth in CytoDyns Annual
Report on Form 10-K for the fiscal year ended May 31, 2015 and other reports filed with the U.S. Securities and Exchange Commission.
Media:
Nader Pourhassan, Ph.D.
Office: 360-980-8524
E-mail:
npourhassan@cytodyn.com
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2023 to Apr 2024